ALKERMES | ALKS - Market Capitalization


ALKERMES reported $5.64B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 403.83B 5.2B Dec/2025
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
ALKERMES USD 4.62B 333M Dec/2025
Amgen USD 176.25B 24.32B Dec/2025
Biogen USD 25.82B 5.28B Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Gilead Sciences USD 152.28B 14.55B Dec/2025
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
J&J USD 500.24B 67.44B Dec/2025
Malin Corporation EUR 142.92M 19.65M Feb/2026
Merck USD 261.26B 51.62B Dec/2025
Nektar Therapeutics USD 14.34B 13.48B Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Otsuka Holdings JPY 4.82T 550.59B Dec/2025
Ovoca Bio EUR 6.12M 4.93M Apr/2026
Pfizer USD 141.57B 6.48B Dec/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025